PACS Group (PACS) is back on investors’ radar after a recent Form 4 filing highlighted insider share sales, arriving alongside rising institutional ownership and the ongoing expansion of its skilled nursing and senior care facilities.

At a recent share price of US$37.77, PACS Group has seen a 12.04% 90 day share price return and a very large 1 year total shareholder return of 196.24%. This suggests momentum has been building alongside facility expansion, higher institutional ownership and the latest insider filings.

If PACS Group’s move has caught your attention, this can be a good moment to see what else is setting up interestingly in healthcare, including 38 healthcare AI stocks.

With PACS Group trading at US$37.77, a P/E of 23.51 and an indicated intrinsic discount of about 31%, the key question is whether this stock still offers value or if the market is already pricing in future growth.

Price-to-Earnings of 24.5x: Is it justified?

PACS Group currently trades on a P/E of about 24.5x, which sits above both its peer group average of 17x and the broader US Healthcare industry average of 23.4x.

The P/E multiple compares the current share price to earnings per share and is a common way investors gauge how much they are paying for each dollar of profit. For a company like PACS Group, which operates skilled nursing and senior care facilities, this highlights how the market is weighing its profitability profile against other listed healthcare operators.

On one hand, PACS Group is flagged as good value against an estimated fair P/E of 42.5x and is trading at an indicated 31.4% discount to an assessed fair value, as well as below an internal future cash flow value estimate of $55.03 per share. On the other hand, its current 24.5x P/E is described as expensive relative to both direct peers on 17x and the wider US Healthcare sector on 23.4x. This suggests the market is already paying a premium versus many competitors, even if some models point to further upside as earnings and cash flows evolve.

Compared with the US Healthcare industry average of 23.4x, PACS Group’s 24.5x P/E sits slightly higher, implying investors are assigning a richer earnings multiple than the sector median. Against the 17x peer average, that premium looks stronger, and any move toward the higher fair P/E level of 42.5x would require the market to place substantially greater weight on PACS Group’s profit profile than it currently does.

Result: Price-to-Earnings of 24.5x (OVERVALUED)

However, PACS Group’s premium P/E and heavy reliance on US healthcare facilities mean any shift in reimbursement trends or facility demand could quickly challenge the current valuation.

Another view on PACS Group’s value

While the P/E comparison suggests PACS Group screens as expensive against peers, the SWS DCF model paints a different picture. The model estimates a future cash flow value of $55.03 per share versus the current $37.77 price. That indicates PACS may be trading at a sizeable discount, so which signal should you give more weight?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out PACS Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of optimism and caution around PACS Group leaves you curious, consider taking the opportunity while interest is high to review the underlying data, including its 4 key rewards

Looking for more investment ideas beyond PACS Group?

Once you have formed a view on PACS Group, broaden your watchlist with other opportunities that match different risk, income, and valuation preferences.

• Target potential value opportunities by scanning companies trading below assessed worth with the 44 high quality undervalued stocks.
• Strengthen your focus on capital preservation by reviewing the 66 resilient stocks with low risk scores for stocks with lower risk scores.
• Spot overlooked opportunities with solid fundamentals by checking the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.